Company Celltrion, Inc. Korea S.E.
Equities
068270
KR7068270008
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- KRW | - |
Apr. 24 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
Apr. 17 | Celltrion, Inc. announces an Equity Buyback for 436,047 shares. | CI |
Business Summary
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
86.1
%
| 1,937,469 | 84.8 % | 1,873,430 | 86.1 % | -3.31% |
Chemical Drugs
23.0
%
| 653,519 | 28.6 % | 500,777 | 23.0 % | -23.37% |
Reconciling Items
-9.3
%
| -310,898 | -13.6 % | -202,919 | -9.3 % | -34.73% |
Others
0.2
%
| 3,877 | 0.2 % | 5,143 | 0.2 % | +32.66% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
97.1
%
| 2,090,465 | 91.5 % | 2,113,156 | 97.1 % | +1.09% |
Asia
2.9
%
| 62,069 | 2.7 % | 63,275 | 2.9 % | +1.94% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 49 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Sung-Han Lee
CMP | Compliance Officer | 42 | - |
Yoon-Mo Koo
PRN | Corporate Officer/Principal | 54 | - |
Sang-Joon Lee
PRN | Corporate Officer/Principal | 57 | - |
Shin-Jae Jang
PRN | Corporate Officer/Principal | 60 | - |
Jung-Won Yoon
PRN | Corporate Officer/Principal | 57 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Soon-Woo Lee
BRD | Director/Board Member | 73 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 66 | - |
Dong-Il Kim
BRD | Director/Board Member | 65 | 08-07-16 |
Joseph Lee
BRD | Director/Board Member | 66 | 08-07-16 |
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 07-04-23 |
Geun-Young Kim
BRD | Director/Board Member | 64 | - |
Dae-Hyeon Yoo
BRD | Director/Board Member | 65 | - |
Hyeok-Jae Lee
BRD | Director/Board Member | 48 | - |
Young-Hye Ko
BRD | Director/Board Member | 69 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 225,966,951 | 143,054,347 ( 63.31 %) | 13,082,991 ( 5.790 %) | 63.31 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
CELLTRION PHARM, INC. 54.81% | 22,797,613 | 54.81% | 1,779,780,238 $ |
CELLTRION, INC. 2.07% | 4,508,124 | 2.07% | 640,262,434 $ |
BIOTOXTECH CO., LTD. 10.22% | 1,631,134 | 10.22% | 7,269,671 $ |
Company contact information
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.64% | 40.57B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B | |
-18.79% | 9.85B |
- Stock Market
- Equities
- A068270 Stock
- 068270 Stock
- Company Celltrion, Inc.